EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rheumatologic Disease as a Substrate for HFpEF: Pathophysiological Mechanisms and Clinical Implications

Maria Dons iD, Morten Sengeløv, Julie Borchsenius, Camilla I Ottosen iD, Marat Fudim iD, Brittany N Weber iD, Harriette G C van Spall iD, Tor Biering-Sørensen iD

Journal of the American Heart Association · 04.08.2026 · 15 (15)

DOI: 10.1161/jaha.125.045770 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 04.08.2026. Verfasst von Maria Dons und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology Copenhagen University Hospital - Herlev & Gentofte. Hospital Heller…. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Rheumatic Diseases, Ventricular Function, Left. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 126 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic inflammation has gained attention in heart failure (HF), particularly HF with preserved ejection fraction (HFpEF); a heterogeneous syndrome representing over half of HF cases and increasingly recognized in individuals with systemic rheumatologic diseases. Although myocardial infarction and HF with reduced EF have traditionally been emphasized in the context of systemic inflammation, recent data suggest that HFpEF is the predominant phenotype, often arising independently of overt coronary artery disease. Despite substantial cardiovascular morbidity and mortality, patients with rheumatologic disease remain underrepresented in HF research, and the mechanisms linking inflammation to HFpEF remain underdescribed in this population. This review examines the intersection of systemic rheumatologic disease and HFpEF, focusing on shared pathophysiology, diagnostic challenges, and therapeutic opportunities. Patients with rheumatologic diseases, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and systemic sclerosis, exhibit a markedly increased risk of HFpEF. Chronic inflammation, microvascular dysfunction, and myocardial fibrosis emerge as key drivers. These conditions complicate diagnosis because of atypical symptoms and overlapping comorbidities. Although existing HFpEF therapies primarily target hemodynamic and metabolic contributors, they seldom address immune‐mediated mechanisms. Anti‐inflammatory strategies have shown cardiovascular benefit in selected populations; yet their role in HFpEF among rheumatologic subgroups remains underexplored. Exclusion of patients with rheumatologic disease or immunosuppressive therapy from HFpEF trials further limits generalizability. In conclusion, HFpEF associated with rheumatologic disease represents a distinct, underrecognized inflammatory phenotype. Collaborative cardiology‐rheumatology research is needed to refine diagnosis, evaluate immunomodulatory strategies, and design inclusive clinical trials to improve outcomes in this growing population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeRheumatic DiseasesVentricular Function, LeftHumansInflammationAnimals

Stichwörter der Autor:innen

autoimmunitycardiorheumatologyheart failureheart failure with preserved ejection fractionrheumatologic diseasesystemic inflammation

Autor:innen und Institutionen

  • Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology Copenhagen University Hospital - Herlev & Gentofte. Hospital Hellerup Denmark.
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences University of Copenhagen Denmark.
  • Duke University Medical Center Durham NC USA.
  • Duke Clinical Research Institute Durham NC USA.
  • Cardio-Rheumatology Program, Divisions of Cardiology and Rheumatic Diseases, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA.
  • Cardio-Dermatology Program, Division of Cardiology, Departments of Internal Medicine and Dermatology University of Texas Southwestern Medical Center Dallas TX USA.

ORCID-Profile: Maria Dons, Camilla I Ottosen, Marat Fudim, Brittany N Weber, Harriette G C van Spall, Tor Biering-Sørensen

Zitieren

APA

Dons, M., Sengeløv, M., Borchsenius, J., Ottosen, C. I., Fudim, M., Weber, B. N., van Spall, H. G. C., & Biering-Sørensen, T. (2026). Rheumatologic Disease as a Substrate for HFpEF: Pathophysiological Mechanisms and Clinical Implications. Journal of the American Heart Association, 15(15). https://doi.org/10.1161/jaha.125.045770

Vancouver

Dons M, Sengeløv M, Borchsenius J, Ottosen CI, Fudim M, Weber BN, et al. Rheumatologic Disease as a Substrate for HFpEF: Pathophysiological Mechanisms and Clinical Implications. Journal of the American Heart Association. 2026;15(15). doi:10.1161/jaha.125.045770

BibTeX
@article{Dons2026,
  author = {Dons, Maria and Sengeløv, Morten and Borchsenius, Julie and Ottosen, Camilla I and Fudim, Marat and Weber, Brittany N and van Spall, Harriette G C and Biering-Sørensen, Tor},
  title = {Rheumatologic Disease as a Substrate for HFpEF: Pathophysiological Mechanisms and Clinical Implications},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {15},
  doi = {10.1161/jaha.125.045770}
}
Kostenlos starten →